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Abstract
Objective To give a comprehensive overview of fetal doses
reported in the literature when imaging the pregnant woman
with suspected pulmonary embolism (PE).
Methods A comprehensive literature search in the PubMed,
MEDLINE and EMBASE databases yielded a total of
1,687 papers that were included in the analysis and have
been analysed with regard to fetal dose in suspected PE
radiological imaging strategies.
Results Fetal dose in chest computed tomography (CT)
ranges between 0.013 and 0.026 mGy in early and 0.06–
0.1 mGy in late pregnancy compared with 99mTc-MAA
perfusion scintigraphy with a fetal dose of 0.1–0.6 mGy in
early and 0.6–0.8 mGy in late pregnancy.
99mTc-aerosol
ventilation scintigraphy results in 0.1–0.3 mGy. However,
there is concern about female breast irradiation in CT,
which is higher than in scintigraphy. CT radiation risks for
breast tissue remain unclear.
Conclusion Knowledge of dosimetry and radiation risks is
crucial in the radiological work-up of suspected PE in
pregnancy. It is reasonable to reserve scintigraphy for
pregnant patients with normal chest radiography findings
and no history of asthma or chronic lung disease.
Performing CT applying dose reduction instead of scintig-
raphy will minimise fetal radiation dose and maximise the
diagnostic value.
Keywords Pulmonary embolism.Radiation protection.
Tomography.Spiral computed.Radionuclide imaging
Introduction
Work-up of pulmonary embolism (PE) in pregnancy
remains a diagnostic dilemma. The morbidity and mortality
in the context of pregnancy-related PE in the developed
world is well known [1–4]. In pregnancy the clinical
diagnosis of both deep-vein thrombosis and PE is generally
difficult and is further complicated because dyspnoea,
tachypnoea, swelling and discomfort in the legs are
common/expected symptoms of pregnancy and must be
interpreted with caution. As the rate of PE in pregnancy is
five-times higher than for non-pregnant women of the same
age, precise PE diagnosis in pregnancy is vital [5].
In thecriteria of Wells et al. [6], the most frequently used
tool for assessing the clinical probability of PE, pregnant
patients were excluded in the validation of the criteria.
Therefore estimating the pre-test probability for PE can be
difficult. Even the D-dimers are known to show special
dynamics during pregnancy [5]. New reference ranges for
normal D-dimer levels for each trimester and novel serum
markers such as the fibrin monomer complex may play a
future role in the management of suspected PE in pregnant
patients [7, 8]. Therefore, estimating the pre-test probability
for PE can be difficult.
T. Niemann (*):G. Bongartz
Department of Radiology, University Hospital,
Petersgraben 4,
4031 Basel, Switzerland
e-mail: niemannt@uhbs.ch
G. Nicolas: J. Müller-Brand
Department of Nuclear Medicine, University Hospital,
Petersgraben 4,
4031 Basel, Switzerland
H. W. Roser
Department of Radiology, Radiological Physics,
University Hospital,
Petersgraben 4,
4031 Basel, Switzerland
Insights Imaging (2010) 1:361–372
DOI 10.1007/s13244-010-0043-6Unnecessary treatment of PE must be prevented as
treatment is associated with probable and critical side
effects for both mother and fetus [9].
In the literature there is controversy as to which
radiological imaging strategy is optimal in suspected
pregnancy-related PE with regard to fetal radiation dose.
The increasing use of CTcauses concern about the safety
and efficacy of this modern technology. The Safety and
Efficacy in Computed Tomography (SECT) project, sup-
ported by the EC-EURATOM 6th Framework Program
[10], is aimed at dose reduction by the justification and
optimisation of CT. Recent publications support the
concern expressed in the SECT project [11, 12].
In general, but especially when young or pregnant
patients are concerned, it must be aimed at optimising
policies in diagnostic imaging with regard to decreasing
radiation dose as far as possible. In the assessment of
suspected pulmonary embolism in pregnant patients, work-
up should begin with tests that provide diagnostic informa-
tion with the use of little or no ionising radiation as chest
radiography and ultrasound. If these tests prove to be non-
diagnostic, further imaging such as lung scintigraphy or CT
pulmonary angiography (CTA) should be performed
[9, 13].
Currently there are two major roentgenological pathways
in the radiological work-up of suspected PE in pregnancy.
Before their application, clinical risk stratification and
laboratory tests as well as lower limb compression
ultrasound should be performed in all pregnant patients.
One main diagnostic algorithm is the scintigraphic work-
up with either combined ventilation/perfusion scans (V/Q)
or solitary perfusion imaging. The other major pathway is
the routinely performed CTA using dose reduction meas-
ures to protect the mother and especially the fetus from
unnecessary radiation.
Recent surveys show that there is limited understanding
and level of awareness among healthcare professionals
about dosimetry and radiation risks associated with imaging
pregnant women [14].
Understanding of the estimated exposure dose to the
fetus permits rational and adequate choices of the imaging
strategies. The purpose of this paper is to give an overview
of the literature and compare the two major imaging
strategies with regard to the fetal dose in suspected PE.
Data extraction
A comprehensive computer literature search of abstracts
was performed to identify articles on fetal dosage in chest
CT or scintigraphy for suspected PE. Initially the PubMed
databases were used with the following search query:
(“pulmonary embolism”[MeSH Terms] OR ((“pulmo-
nary”[tiab] OR “lung”[tiab]) AND “embolism”[tiab]))
AND (“pregnancy”[MeSH Terms] OR “pregnant”[tiab]
OR “fetus”[MeSH Terms] OR “fetus”[tiab])
The initial search query yielded a total of 1,687 articles.
The search query was translated accordingly for the
MEDLINE (and EMBASE) databases, but retrieved no
further articles.
The analysis was limited to papers published after 1990
with the rationale that before 1990 the technical equipment
was substantially different to that currently used. The
search was further restricted to the English, French, Spanish
and German languages. Case reports were excluded. Two
observers independently checked all retrieved studies for
inclusion. Disagreements were resolved in consensus.
These limitations resulted in a total of 497 articles.
Further title and abstract clearing of non-relevant articles
yielded a total of 85 papers that could be used for the
literature review (Fig. 1). Extensive cross-checking of
references was performed.
CTA pathway
CTA has gained widespread acceptance as the new standard
of reference for suspected PE in the general population
because of its high sensitivity and specificity [15–20]. See
Table 1 for an overview of the studies discussed.
Hurwitz et al. [21] used an anthropomorphic phantom to
determine fetal doses from a range of multidetector-row CT
Papers before 
1990 excluded
n =   830
Case reports 
excluded, 
language 
limitations 
n =   360
Excluded by 
title/ abstract  
clearing
n =  412 
Potentially appropriate articles 
to be included in review
titles, abstracts: n =   497
Included in comprehensive 
analysis
n =   85  
Potentially relevant articles
titles, abstracts: n =  1687 
Potentially relevant articles
titles, abstracts: n =   857
Fig. 1 Results of the comprehensive literature search
362 Insights Imaging (2010) 1:361–372investigations in the early stages of pregnancy. They varied
the position of the uterus during the first three months of
pregnancy. A routine CT protocol was applied for the
simulations without any dose reduction measures (140 kV,
380 mAs, DLP 507.3 mGy cm, CTDIvol 28.39 mGy, 16×
1.25 mm collimation). The fetal radiation dose recorded
from this protocol was less than 0.7 mGy (0.24–0.47 mGy
for 0 months and 0.6–0.66 mGy for 3 months of pregnancy).
Doshi et al. [22] used an anthropomorphic phantom to
evaluate fetal dose in late pregnancy. The phantom
underwent imaging with different equipment with varied
technical parameters. Mean fetal absorbed dose was
calculated as 0.23–0.6 mGy, whereas an imaging protocol
using contemporary equipment and recent technical param-
eters resulted in a range of 0.06–0.1 mGy. Further fetal dose
reduction could be accomplished using different dose
reduction strategies. Automatic tube current modulation
resulted in a 10% further decrease in dose; anterior
abdominal lead shielding (positioning the lead out of the
imaging field) yielded a 35% dose reduction. Imaging with
a 5-cm shorter image length in the lung bases resulted in
55% dose reduction.
Another approach based on Monte Carlo simulations
was performed by Winer-Muram et al. [23]. Maternal-fetal
geometries of 23 patients were used for the analysis. A
serial routine CT protocol was used for calculation of the
imaging parameters (120 kV, 100 mAs). Mean fetal doses
were estimated for all trimesters as follows: 0.0033–
0.02 mGy first trimester; 0.0079–0.076 mGy second
trimester; and 0.051–0.130 mGy, third trimester.
Nijkeuter et al. [24] applied published conversion factors
to estimate the dose to the uterus and hence the fetus in
early pregnancy. A standard chest CT protocol for 16-row
multidetector (MD) CT was used for image acquisition
(120 kV, 85 mAs). The equivalent dose to the fetus was in
the region of 0.013 mGy. Using a single-row system
(120 kV, 250 mAs) resulted in a fetal equivalent dose of
0.026 mGy. The calculations based on the assumption that
the amount of radiation absorbed by the fetus was assumed
to be equal to that absorbed by the uterus of a non-pregnant
woman.
Another calculation performed by Huda [26] retrieved a
fetal dose of ~0.14 mGy. The trimester of pregnancy was
not further specified, but, taking into account the location of
the fetus of at least 20 cm, later pregnancy must be
assumed. The data were based on the dose measurements of
Boone et al. [25]. A tube voltage of 120 kV was used and
150 mAs tube current, the system type was not further
specified.
Damilakis et al. [27] provided fetal dose measurements
using anthropomorphic phantoms for third trimester simu-
lations. For chest CT examination they used a standard
protocol (120 kV, 200 mAs) for a single slice system. Dose
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Insights Imaging (2010) 1:361–372 363calculations based on manual segmentation of the fetal
position resulted in a mean fetal dose of 1.2 mGy for late
pregnancy.
Cook and Kyriou [28] reported an absorbed dose to the
fetus of 0.01 mGy for CTAwithout specifying the trimester.
No technical parameters for the CT protocol used or any
scanner details were specified.
The International Commission of Radiation Protection
(ICRP) further published mean fetal doses for different
radiological examinations. The approximate mean fetal
dose from chest CT was reported to be 0.06 mGy [29] for
single-detector-row helical CT. No further technical speci-
fications were mentioned, nor the trimester specified.
Mean fetal doses/estimates of uterine dose published by
the National Radiological Protection Board (NRPB) are
noted as 0.06 mGy using a single-slice system [30] without
further specifying imaging parameters or the trimester.
Scintigraphy pathway
In the era of CTA ventilation-perfusion (V/Q) imaging has
become the second-line imaging technique for suspected
PE. As many other conditions such as pneumonia or
bronchospasms may cause perfusion defects in lung
scintigraphy ventilation imaging is used routinely to
match/mismatch these defects [31].
In many centres, the relatively low incidence of lung
comorbidity in pregnancy allows perfusion scintigraphy to
be performed using “half-dose” (40 MBq
99mTc-MAA)
without the need for ventilation imaging [29, 32]; prese-
lection of these patients based on normal chest radiography
is important to prevent non-diagnostic images. Extending
imaging duration may enhance image quality in this context
of dose-reduced lung perfusion. The interpretation of lung
perfusion scintigraphy is usually straightforward in preg-
nant patients because of the low frequency of comorbid
pulmonary disorders [33].
In nuclear medicine, fetal doses depend predominantly
upon the administered activity. In very ill patients there may
beindividualdifferencesinmetabolismanddistributionofthe
radiopharmaceuticals. Conversely, pregnant women in most
cases have essentially normal distribution of radiopharma-
ceuticals and fetal doses can be reasonably estimated.
Perfusion scintigraphy
99mTc-labelled macro-aggregated human albumin particles
(MAA) are injected into a peripheral vein leading to
pulmonary micro-embolisation. To obtain uniform distribu-
tion of activity reflecting regional perfusion, a minimum of
60,000 particles is required [34]. In the usual non-pregnant
adult, normally about 400,000 labelled particles are
injected.
A reduction in the number of particles administered to
between 100,000 and 200,000 is recommended in patients
with known pulmonary hypertension, right to left heart
shunt or after a single lung transplantation [35].
99mTc is
excreted via the kidneys and while in the bladder it will
contribute to the fetal dose. The biological half-life of
pertechnetate
99mTc is 55–108 min [36]. See Table 2 for an
overview of the studies discussed.
Using a low-dose perfusion protocol of 40 MBq
99mTc-
MAA, Nijkeuter et al. [24] published a fetal radiation dose
of 0.11–0.2 mSv; the term of pregnancy was not further
specified. Again, as in their fetal dosimetry for CT, the
calculations were based on the assumption that the amount
of radiation absorbed by the fetus was equal to that
absorbed by the uterus of a non-pregnant woman.
Cook and Kyriou [28] reported a fetal dose of 0.12 mGy
for perfusion scintigraphy, also using low-dose perfusion
imaging (50 MBq
99mTc); neither further technical details
nor term of pregnancy were further specified.
In publication 84, the ICRP published fetal dose
estimations for early and late pregnancy using 200 MBq
99mTc for the calculations [29]. A fetal dose of 0.4–
0.6 mGy was estimated in early pregnancy, whilst in late
pregnancy a dose of 0.8 mGy was reported.
Mean fetal doses of 0.21–0.3 mGy in early pregnancy
were described by Hurwitz et al. [21] using 74 MBq of
99mTc-MAA.
Huda [26] reported fetal doses of 0.9 mGy for 370 MBq
99mTc-MAA perfusion imaging, based on old numbers from
the ICRP [37].
Russel et al. [38] published mean fetal doses for different
stages of pregnancy. Using 200 MBq
99mTc-MAA they
published 0.6 mGy for the first trimester, 0.75 mGy for the
second trimester and 0.6 mGy for the third trimester.
The NRPB published fetal doses of 0.2 mGy for
perfusion imaging with
99mTc-MAA [30]. No technical
details or trimester were specified.
Ventilation scintigraphy
The choice of radiopharmaceuticals for the ventilation
portion of the lung imaging can also affect fetal dose. A
ventilation study can be performed using either noble gases,
such as
133Xe gas and
81mKr, or aerosolised
99mTc
diethylenetriaminepentaacetic acid (DTPA) and Technegas.
Using
133Xe results in a very low embryo dose
(<0.01 mGy). The inhalation of approximately 110 MBq
99mTc DTPA will result in an embryo dose of about
0.9 mGy [37]. It is absorbed through the lung and excreted
via the kidneys, and while in the bladder it will contribute
to fetal dose. The biological half-life of
99mTc-Technegas
(an ultra-fine suspension of carbon nano-particles labelled
with technetium) is 135 h [39].
364 Insights Imaging (2010) 1:361–372In the case of suspected PE, the perfusion imaging can
be performed first, and if it is normal, ventilation imaging
may not be needed at all. Therefore, ventilation imaging in
pregnancy should only be performed in exceptional cases
and not using
99mTc-aerosols to minimise fetal radiation
exposure. Even in the non-pregnant population the diag-
nostic value of perfusion imaging only combined with chest
radiography seems underestimated. Recent publications
show that a turn back to older imaging algorithms using
chest radiography and perfusion scintigraphy provide
diagnostic accuracy similar to CTA [40]. See Table 3 for
an overview of the studies discussed.
Nijkeuter et al. [24] measured fetal dose using 600 MBq
81mKr-aerosol gas in a 2-min rebreathing protocol, resulting
in a dose of 0.0001 mGy.
The ICRP published dose estimates for fetal radiation
using 40 MBq
99mTc-aerosol. Fetal dose was estimated to be
0.1–0.3 mGy in early and 0.1 mGy in late pregnancy [29].
Again using 40 MBq
99mTc-DTPA aerosol, Russel et al.
[38] reported a fetal dose of 0.17 mGy in the first trimester,
0.092 mGy in the second trimester and 0.12 mGy in the third
trimester of pregnancy. Using
133Xe rebreathing protocols
resulted in 0.000015–0.000048 mGy fetal radiation.
The fetal radiation dose absorbed by maternal ventilation
imaging was calculated, based on the data of Hurwitz et al.
[21], as 0.15 mGy in early pregnancy and 0.02 mGy in late
pregnancy with 5-min maternal rebreathing of 370 MBq
133Xe. Another protocol using 740 MBq
133Xe breath-hold
without maternal rebreathing resulted in 0.04 mGy in early
and 0.01 mGy in late pregnancy.
The NRPB published fetal doses of up to 1.5 mGy for
ventilation imaging using
99mTc-aerosols [30].
Discussion
Direct dose measurements or calculations/estimates of fetal
dose in chest CTare difficult to perform and in the literature
a variety of doses is reported, most probably due to the
background that fetal dose in chest CT is dependent on the
position and size of the fetus as well as on the trimester of
pregnancy [22]. A recent article published by the American
College of Radiology points out that dose calculation is a
very complex issue because absorption in each organ is
variable from patient to patient [41].
Whether scintigraphy or CTA should be the preferred
imaging technique remains a controversially debated topic.
Already the PIOPED I trial showed that more than 60% of
V/Q imaging is non-diagnostic and additional diagnostic
studies might be pursued, as the probability of PE is still
considerable. This may result in delay and more radiation
exposure, which is not desirable in pregnancy [31, 42].
However, a substantial reduction in the proportion of non-
diagnostic scintigraphy studies has been achieved since
PIOPED [43, 44]. In a recent publication, lung scintigraphy
had a lower diagnostic inadequacy rate than CTA in
Author Fetal dose (mGy)
1st trimester 2nd trimester 3rd trimester
99mTc-MAA
Nijkeuter 2004 [24] 0.11–0.2 ––40 MBq
Cook 2005 [28] 0.12 trimester nfs – 50 MBq
Hurwitz 2006 [21] 0.21–0.3 ––74 MBq
ICRP 2000 [29] 0.4–0.6 – 0.8 200 MBq
Russel 1997 [38] 0.6 0.75 0.6 200 MBq
Table 2 Studies reporting fetal
doses for perfusion scintigraphy
in suspected PE (nfs not further
specified)
Table 3 Studies reporting fetal doses for ventilation scintigraphy (nfs not further specified)
Author Fetal dose (mGy)
1st trimester 2nd trimester 3rd trimester Activity Radionuclide Specials
Nijkeuter 2004 [24] 0.0001 Trimester nfs 600 MBq
81mKr-aerosol gas 2 min rebreathing
Hurwitz 2006 [21] 0.15 – 0.02 370 MBq
133Xe-aerosol gas 5 min rebreathing
Hurwitz 2006 [21] 0.04 – 0.01 740 MBq
133Xe-aerosol gas Breathhold
Russel 1997 [38] 0.000015–0.000048 Trimester nfs nfs
133Xe-aerosol gas Rebreathing
NRPB 1993 [30] 1.5 Trimester nfs nfs
99mTc-aerosol –
ICRP 2000 [29] 0.1–0.3 – 0.1 40 MBq
99mTc-aerosol –
Russel 1997 [38] 0.17 0.092 0.12 40 MBq
99mTc-aerosol –
Insights Imaging (2010) 1:361–372 365pregnant patients [45], probably due to a transient interrup-
tion of contrast material by unopacified blood from the
inferior vena cava in the CTA studies. Still, today, the
standard assumption in radiological practice remains that
work-up of suspected LE in pregnant women should be
performed by scintigraphy because of the lower quantity of
radiation administered to the fetus.
International recommendations
In the literature, even international recommendations
remain unclear as to whether to use scintigraphy or CTA
for pregnant patients.
Several national and international societies, such as the
Fleischner Society or the PIOPED II investigators, recom-
mend D-dimer assessment and the use of ultrasound instead
of CT or scintigraphy as the first-line imaging test for the
evaluation of pregnant patients [20, 46, 47]. According to
the guidelines of the German Society of Radiology, CT is
the preferred technique because of the lower radiation dose
to the uterus, but clinical risk assessment and combined D-
dimer testing is recommended before imaging strategies are
attempted [46].
If imaging with ionising radiation is necessary, both CT
angiography and ventilation-perfusion lung imaging can
provide useful information; however, CT might be the
preferred technique because of exposure of the conceptus to
lower doses [48].
The British Thoracic Society guidelines give no specific
recommendations for imaging pregnant patients for sus-
pected PE, but declare CT to be the initial lung imaging
technique in the general patient. Isotope lung imaging may
be considered if several quality criteria are fulfilled [47].
In a statement by the Fleischner Society, strategies for
pregnant patients were briefly discussed, but with no direct
recommendations being given [20]. However, even among
the PIOPED II investigators the discussion remained
controversial. Most of the PIOPED II investigators recom-
mended D-dimer assessment and ultrasound before perfu-
sion scintigraphy for suspected pulmonary embolisms in
pregnant patients [15, 48].
Fetal radiation dose
Many methods for the estimation of fetal dose in pregnant
patients undergoing CT examinations assumed early term
pregnancy in a single-size patient model with an average,
uniform maternal anatomy. These dose estimates did not
take into account maternal anatomy variances, natural
variations, such as fetal presentation, and gestational age.
Differences in these attributes can cause failures in
estimation of fetal dose of up to 100% at radiological
examinations [49, 50]. The fetal dose will increase during
pregnancy both as the fetus grows in size and as it moves
closer to the imaging volume [23].
In the first trimester of pregnancy, the absorbed dose to
the uterus may be used as a substitute for the absorbed dose
to the embryo. Similarly, the absorbed dose to the fetus
from radioactive substances without placental transfer is
expected to be within the same range as the dose to the
uterus. In the case of radioactive substances with placental
transfer, the absorbed dose to organs and tissues of the
mother may, as a first approximation, be taken as
representative of the absorbed dose to the corresponding
organs and tissues of the fetus [51].
In CTA, the fetus is only exposed to scatter radiation
assuming appropriate planning of the examination. Inad-
vertent irradiation of a fetus most frequently occurs during
the early post-conception period, when the woman is
unaware of her pregnancy. In early pregnancy, the distance
from the directly irradiated region at the base of the lung to
the location of the embryo is generally at least 20 cm,
where the scattered radiation level would be no more than
1% of the chest dose [25].
The risks of causing a range of different radiation effects
depend on the gestational age [52]. In fact, in the pre-
implantation embryo, there is no measurable risk of
malformation regardless of the amount of radiation expo-
sure, and the greatest concern is death of the embryo.
Within the first 2 weeks of embryonic age, there is a 2%
risk of the blastocyst failing to implant, causing death of the
embryo when the irradiation dose is greater than 0.1 Gy. If
the embryo survives there is likely to be no increased risk
[53, 54].
During the first two trimesters the fetus is most
susceptible to deterministic teratogenic effects, but it is
assumed that the fetus is not at risk if the irradiation dose
does not exceed a threshold dose [55]. None of the studies
analysed explicitly reported fetal doses when applying dose
reduction measures such as lead shielding or automatic
exposure control (AEC), only relative changes in percent-
age. Therefore, the absolute fetal dose using recent imaging
technology including dose reduction strategies must be
estimated to be lower than those reported.
Meeting the threshold for inducing deterministic effects
as malformations or reduction in intelligence is not likely
with the expected doses in CT or in V/P imaging either;
thus, the most important consideration is induction of
childhood cancer. As in all examinations in radiology, there
is always a stochastic risk of carcinogenesis, and also in the
fetus after in utero irradiation, regardless of the dose.
Despite the fact that fetal radiation dose for both CTA and
scintigraphy examinations in suspected pregnancy-related
PE must be seen to be very low, further reduction must be
aimed at during pregnancy. The risks of low-level radiation
are difficult to quantify and the risk of malignancy is
366 Insights Imaging (2010) 1:361–372known to be increased in persons that have been exposed to
radiation in utero [56]. However, many effects of radiation-
induced childhood cancer still remain controversial [57].
The fetal doses in CTA reported in the literature are well
below the 100-mGy threshold reported to be relevant for
deterministic effects [29]. The fetal dose of 50 mGy is
considered as the limit below which there is no harm from
deterministic effects and the risk of stochastic effects
is <1% [58]. There is no evidence that the pattern of cancer
induction varies with gestational age and the risk is likely to
be constant over the entire pregnancy [59]. The number of
excess malignancy cases up to the age of 15 years
following irradiation in utero is considered to be 1 in
16,000 per mSv [59]. This equates to an additional risk of
malignancy of 1 in 560,000 following half-dose perfusion
scintigraphy and 1 in 1,000,000 after CT pulmonary
angiography [28]. Other publications report the excess risk
of the induction of childhood cancer to be 1 in 33,000 per
mGy [52]. In addition, the excess relative risk of develop-
ing childhood cancer has been estimated to be approxi-
mately 0.28 at 1.0 mGy in the first trimester, 0.03 at
1.0 mGy in the third trimester, and overall 0.037 at
1.0 mGy during pregnancy [59]. A recent paper reports
the probability of giving birth to a healthy baby decreases
by only 0.5% even when performing routine dose level
biphasic CT of the abdomen [60]. The fetal dose level for
chest CT is far beyond these estimated dose values [60].
Fetal threshold doses and risks in different gestational
periods have been outlined extensively [61].
The natural background radiation dose to the fetus
during pregnancy is approximately 1 mGy [57]. By
comparison, exposure of at least 100 mGy is necessary
before pregnancy termination is considered [42].
In chest CT, the fetal doses reported for specified
trimesters range between 0.003 and 0.47 mGy in the first
trimester [21, 23, 24, 26]. Two studies determined fetal
dose measurements in the second trimester of pregnancy to
be 0.0079–0.66 mGy [21, 23]. A variance of a factor of
about 80 could be observed. For the third trimester, a wide
variety of fetal doses was reported, such as 0.051–1.2 mGy,
differing by a factor of nearly 30 [22, 23, 27].
Similarly the high fetal doses reported by Hurwitz et al.
[21] must be reviewed critically. These were the only
authors using a tube current of 140 kV, together with a high
tube current product of 380 mAs for the imaging of
pregnant patients. Therefore, we attribute the high reported
fetal dose of 0.24–0.66 mGy in the first trimester to the
selection of technical parameters for both tube current and
tube voltage, which were above recent recommendations.
Conversely, Winer-Muram et al. [23] calculated very low
fetal doses. Fetal and uterus dimensions were precisely
measured in 23 pregnant women, who formed the basis for
the dose calculations. The imaging parameters used were
reasonable (120 kV, 100 mAs, pitch 1), but the imaging
distance was described as 11 cm from just inferior to the
xiphoid process to the aortic arch. We do not estimate this
image length to be sufficient to rule out maternal PE
properly. Using commercial dosimetry tools [62], the image
length to cover the whole lungs is around 24 cm. Even
reducing the basal image length, as has been proposed in
the literature, results in an image length of 19 cm [22]. The
amount of fetal radiation in the calculations might not
reflect the scatter radiation in routine chest CT examina-
tions for suspected PE. Therefore, we think that the fetal
doses reported from Winer-Muram and co-workers cannot
be associated with an image length covering the whole
lungs.
The fetal doses reported for perfusion scintigraphy are
all very consistent for all trimesters [21, 24, 28, 29, 38].
Reducing administered activity of
99mTc-MAA to 25%
equally reduces the fetal dose calculated. Therefore,
possible dose reduction can be performed easily and
straightforwardly. However, a minimum of 60,000 particles
is required [34]; thus, there are clearly limits in further fetal
dose reduction.
Exclusion of the CTA data discussed above leaves us
with only the data published by Nijkeuter et al. [24] and,
therefore, CTA mean fetal doses of 0.013 mGy in the first
trimester using recent multislice technology. For the second
trimester no data remain to be discussed. However, as fetal
size increases, the dose must be assumed to be somewhere
between the first and third trimester data. In the third
trimester at least two studies remain to give an average fetal
dose of 0.06–0.14 mGy [22, 26]. These data are consistent
with the average doses reported for the whole pregnancy,
which range between 0.01 and 0.06 mGy [28–30].
Taking into account recent recommendations to perform
perfusion scintigraphy with “half dose” activity, perfusion
scintigraphy resulted in mean fetal doses of 0.177 mGy (SD
0.095) for all trimesters based on the data analysed [24, 28].
Ventilation imaging can and should be avoided in
pregnant women if perfusion imaging is within normal
limits. The fetal radiation dose strongly depends on the
substances used for inhalation. Noble gases such as
81mKr
and
133Xe should be preferred over
99mTc-aerosols.
There is a reported overall excess relative risk of
childhood cancer of 0.037 at 1 mGy of fetal radiation
during pregnancy [59]. In the mother, a risk of radiation-
induced breast cancer of 0.005% for 1 mSv of radiation is
reported [42]. This reflects an absorbed solitary dose of
8.3 mGy calculated with the new tissue weighting factors
for breasts that have been raised from 0.05 to 0.12 [63].
These calculations were performed using a recent imaging
protocol to detect suspected PE using a 16-row system and
commercial dosimetry software [62, 64]. For the CT
protocol applied by Nijkeuter et al. [59] we calculated a
Insights Imaging (2010) 1:361–372 367breast dose of 11 mGy or 1.32 mSv respectively, associated
with a 0.017 mGy fetal dose in the first trimester. Therefore
the maternal breast cancer risk was 0.0066 and the fetal
excess risk of childhood cancer around 0.000476 in early
pregnancy using the numbers of the ICRP. Based on the
numbers by Doshi et al. [22], we calculated for the same
image length and late pregnancy a breast dose of 10 mGy
or 1.2 mSv respectively, associated with 0.1 mGy fetal
dose. Therefore, the maternal breast cancer risk was 0.006
and the fetal excess risk of childhood cancer was around
0.003.
Based on the data analysed for perfusion-only scintigra-
phy the absorbed breast dose is around 0.044 mSv for low-
dose perfusion scintigraphy (74 MBq) and 0.12 mSv for
normal dose scintigraphy (200 MBq). This leads to a
maternal breast cancer risk of 0.0002–0.0006 (74–
200 MBq). For early/late pregnancy a fetal dose of 0.11–
0.6 mGy (74–200 MBq
99mTc-MAA)/0.8 mGy (200 MBq
99mTc-MAA) could be observed. This results in a fetal
excess risk of childhood cancer of around 0.0031–0.17 (74–
200 MBq
99mTc-MAA) in early and 0.024 (200 MBq
99mTc-MAA) in late pregnancy.
Abdominal lead shielding
Maternal abdominal lead shielding has been reported to be
an effective way of reducing fetal scatter radiation [22].
Circumferential lead covering yields in a double dose
reduction to the fetus in comparison with anterior shielding
only [65]. The contribution to the fetal dose of secondary
internally scattered radiation increases with increasing lead
thickness but reaches a plateau at a certain thickness of
lead. The component resulting from secondary internally
scattered radiation is much smaller in magnitude than the
external and primary internal scatter radiation. The primary
internal scatter radiation can be seen as independent of the
thickness of lead used for shielding [66]. Of course,
allowing the shielding to reach the direct radiation exposure
field must be carefully avoided because the automatic tube
current regulation would immediately cause a tremendous
increase in the applied dose.
The effectiveness of performing imaging with internal as
opposed to external abdominal shielding has been demon-
strated in a phantom study using orally administered barium
sulphate to protect the fetus [67].
Tube current
Technological advantages such as automatic tube current
modulation tools should be used in both pregnant and non-
pregnant patients.
Doshi et al. [22] reported an overall dose reduction of
10% using automatic tube current modulation in their
simulation study. Depending on the image noise level other
studies even yielded dose reduction of 32–66% using AEC
[68–71].
Image length
As could be shown in phantom measurements, a reduction
of the image length is a valuable way of reducing the dose
to the fetus. Sparing the lung bases yields significant fetal
dose reduction [65, 72]. Emboli that could be missed on CT
sparing the lung bases are to be found in a subsegmental
distribution. The clinical significance of subsegmental
pulmonary embolism is still debated controversially. It has
been suggested that emboli in the subsegmental pulmonary
arteries do not contribute substantially to morbidity and
mortality, and taking into account the uncertainty regarding
the necessity of treating patients with isolated subsegmental
PE, the clinical impact of the depiction of subsegmental
clots still remains unclear [73–75]. Based on this assump-
tion protocols can be used covering not the whole lung but
sparing the lung bases to maximise the distance between
the fetus and the edge of the image [65, 76].
Maternal breast tissue
Although still debated controversially, radiation dose to the
breast tissue seems to be of critical importance, especially
in girls and young women. Just recently, tissue weighting
factors for breast tissue have more than doubled, taking into
account recent research implying possible elevated radio-
sensitivity [63]. However, CT radiation risks for breast
tissue still remain unclear [77].
In the case of chest CT, it is clear that the maternal organ
at greatest risk is the female breast. In particular, the
proliferating breast tissue in pregnancy seems likely to be at
increased risk. Breast doses have been estimated to be 20–
60 mGy for a CT examination performed for pulmonary
embolism [78–80]. For these breast doses reported, the
authors used technical parameters that should not be
applied in pregnancy, such as tube voltage of 140 kV [79,
80] and a tube current product of a maximum of 304 mAs
[80]. Applying a reasonable tube voltage of 120 kV results
in breast doses of a maximum of 26 mGy based on the
technical parameters reported.
Conversely, injection of
99mTc-MAA results in an
absorbed maternal breast dose of 0.005 mGy/MBq per unit
of activity administered [81]. Dose-reduced perfusion
imaging therefore results in an absorbed breast dose of
0.2–0.37 mGy, assuming administered activity of 40–
74 MBq. Normal dose perfusion imaging with 200 MBq
99mTc-MAA accounts for 1 mGy of breast radiation.
For breast cancer, an associated risk of 0.005% has been
reported for 1 mSv of radiation exposure. Considering the
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develop cancer at some point in their lives, the increased
risk due to CT is very small [42]. Also, some authors try to
push the discussion back to reason and point out that many
clinicians underestimate the risk of radiation, but equally
others massively overestimate the risk [82].
Breast bismuth shields have been evaluated in the
literature to reduce the dose to the female/maternal breast
and are reported to be an effective measure [60, 83].
However, their radiological value still seems to be
controversial, as other authors do not recommend the use
of breast shielding because of the impact on image noise. If
an increase in image noise is accepted, reduction of the tube
current is proposed as an easier and more efficient dose
reduction strategy [84]. Recent articles also promote the use
of AEC for significant breast dose reduction [85].
Iodinated contrast media
Iodinated contrast media are necessary when performing
CTA for suspected PE and both the mother and the fetus are
exposed to intravenous iodinated contrast medium. These
may traverse the placenta and enter the fetal blood, then
excreted by the kidneys into the bladder and actually reach
the amniotic fluid. When the amniotic fluid is swallowed it
enters the gut. Depression of fetal thyroid function is the
chief potential harmful effect of iodinated contrast media
within the fetus [86]. There is still a lack of scientific data on
the amount of free iodine possibly traversing the placenta and
its side effects and consequences for the fetus. When the
mother has received iodinated contrast media, the thyroid
function of the newborn should be checked during the first
week [13, 86].
When performing CTA in pregnancy, deterioration in
pulmonary vessel enhancement has been reported, probably
due to hyperdynamic circulation with increased cardiac
output, increased plasma volume, increased body weight
and the more pronounced effects of a Valsalva manoeuvre
[45, 87]. Use of bolus triggering protocols in the imaging
planning should be preferred over fixed delays to overcome
possible contrast limitations in pregnancy. Further contrast
optimisation has been reported to be achieved with tube
voltage reduction, as the effective energy of the X-ray beam
approaches the absorption k-edge of iodine [72, 87–90]. In
addition substantial dose reduction can be assumed for both
the maternal breasts and the fetus.
Value of chest radiography
A preliminary chest radiograph remains important in all
pregnant patients for the exclusion of alternative readily
diagnosable conditions and maybe to aid in the interpreta-
tion of subsequent tests. The chest radiograph also plays an
important but often overlooked role in triaging subsequent
imaging tests (i.e. scintigraphy or MDCT). For this purpose
a single plane radiograph is absolutely sufficient. It has
been shown that the presence of any abnormality on the
initial chest radiograph decreases the utility of scintigraphy
[91, 92]. The approximate fetal dose from a single plane
chest radiograph is reported to be <0.01 mGy [21, 29].
However, in scintigraphy examinations easy further meas-
ures can also provide dose reduction and increase diagnos-
tic accuracy.
Voiding after scintigraphy
Radionuclides in maternal tissues contribute to fetal dose.
In the case of radiopharmaceuticals that are rapidly
eliminated by the maternal kidneys such as
99mTc, the
urinary bladder may be acting as a reservoir and is a major
source of fetal irradiation. Maternal hydration and frequent
voiding can reduce the fetal dose after the administration of
a number of radiopharmaceuticals, in this context especially
of
99mTc [29].
Value of SPECT scintigraphy
Single photon emission computed tomography (SPECT)
further increases the diagnostic accuracy of the scintigraphy
images using two main methods [32]. One method sums
projections over a limited angular range, while another uses
reconstructed SPECT data projected through an attenuation
map to generate count-rich reprojected planar images [93].
Bajc et al. [94] identified 53% more mismatched regions
with SPECT. In a study by Collart et al. [95], V/PSPECT
increased the specificity for PE from 78% to 96% at similar
sensitivities to CT. Reinartz et al. [96] found a sensitivity
and specificity of 0.76 and 0.85, respectively, with
V/PPLANAR compared with 0.97 and 0.91 with V/PSPECT.
In summary, CTA for PE has the advantage that the fetus is
not directly exposed, but only to scatter radiation. The
estimated radiation exposure is low for CTwhen the fetus is
outside the field of view.
In perfusion scintigraphy, the need for intravenous
injection of the radionuclide tracer will lead to perfusion-
dependent and bladder-reservoir-related direct fetal expo-
sure. In particular, in the first trimester fetal exposure with
CTA is therefore lower than exposure with perfusion
scintigraphy, even if a half-dose scintigraphic technique is
used [24, 28].
For chest CT, most of the studies cited reported mean
fetal dose estimates to be lower by a factor of 10 than the
comparable dose-reduced perfusion scintigraphy protocols.
These estimates did not take into account the different dose
reduction measures possible in CTA. Thus, fetal dose must
Insights Imaging (2010) 1:361–372 369be estimated as being substantially lower for chest CT than
for the scintigraphy pathway.
Based on the data analysed, there is an increased risk of
childhood cancer induction in early pregnancy when using
perfusion scintigraphy of a factor of about 7; even in late
pregnancy the risk is still increased by a factor of about
8 compared with the estimated risk calculated for CTA.
The maternal breast cancer risk was calculated to be
increased about tenfold in CTA compared with perfusion
scintigraphy over the whole pregnancy.
These risk estimates are applied for normal dose perfusion
scintigraphy and CTAwithout dose reduction measures.
With CTA, dose reduction measures such as abdominal
lead shielding, reduced tube current, AEC, reduced tube
voltage and reduced image length the maternal and
especially the fetal dose can be expected to be further
reduced substantially.
In perfusion scintigraphy, dose reduction is directly
related to the activity administered. However, the breast
dose reduction that can be estimated by reducing the
activity administered in perfusion scintigraphy seems to
be far more than can be expected from CT dose reduction
measures.
Conclusion
According to the ICRP, almost always, if a diagnostic
radiology examination is medically indicated, the risk to the
mother of not carrying out the procedure is greater than the
risk of potential harm to the fetus. Radiation doses resulting
from most diagnostic procedures present no substantial risk
of causing fetal death, malformation, or impairment of
mental development [29].
As CTA allows a much wider variety of pathological
conditions to be depicted and as the fetal dose is
substantially lower than with the use of scintigraphy, it is
reasonable for CTA to be performed in suspected
pregnancy-related PE. However, the breast dose absorbed
by the mother is higher than with the use of scintigraphy.
It is reasonable to reserve scintigraphy for patients with
normal chest radiographs without any remarkable findings
and no history of asthma or chronic lung disease. Recent
imaging technology and CT dose reduction strategies
should be applied when imaging pregnant women for
suspected PE. Ventilation scintigraphy using
99mTc-aerosols
should not be performed in pregnancy.
Radiation in pregnancy should be avoided whenever
possible. The risks and benefits of radiation exposure both
to mother and fetus must be weighed up when deciding
imaging strategies in pregnancy.
Overall, the risks to the conceptus are negligible at doses
such as those involved in CT and scintigraphy for PE.
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